share_log

Shockwave Medical Initiates All-Female Coronary Intravascular Lithotripsy Study To Treat Severely Calcified Cardiovascular Disease

Benzinga Real-time News ·  Sep 19, 2022 09:06

EMPOWER CAD isthe First Prospective, Female-Only Study of Coronary Interventions

StudySeeks to Confirm Benefits of Shockwave's Coronary IVL in FemalesWho Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies

SANTA CLARA, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has initiated the first-ever prospective coronary intervention study consisting of all female patients – EMPOWER CAD – to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 Coronary IVL Catheter, which showed similar...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment